Biocept (BIOC: NASDAQ) Investor Relations Material

Overview

Biocept, Inc. has established itself as a significant player within the molecular oncology diagnostics industry, with its innovative portfolio of clinical diagnostic laboratory assays that support oncology patients throughout the continuum of care. Through its proprietary technology, the company can identify rare tumor cells and cell-free tumor DNA in blood and cerebrospinal fluid, enabling healthcare providers to qualify a subset of cancer patients for targeted therapy at various stages of their treatment journey. The firm offers a range of assays for various solid tumor indications, including breast cancer, non-small cell lung cancer, gastrointestinal cancers, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. These tests provide valuable insight into oncogenic alterations that can help clinicians better monitor and manage patient outcomes. Biocept's excellent medical services extend beyond oncology to include ctDNA and ctRNA testing from cerebrospinal fluid tumor cells, which help medical specialists in surgical and radiation oncology develop treatment plans. As a result, the company has enjoyed success in its partnerships with healthcare providers throughout the United States, and it provides clinical trial and research services to pharmaceutical and biopharmaceutical companies to support cancer research efforts. The company has also expanded its technology beyond cancer to address the current COVID-19 pandemic. Biocept has collaborated with CLEARED4 to create a comprehensive COVID-19 testing system that assists its customers in tracking and managing their testing requirements and test results, highlighting its contribution to public health work beyond cancer research. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California. With its pioneering technology, the company has become a vital component in the fight against cancer and is poised to make even greater contributions in the years ahead.